METACLIPSE THERAPEUTICS CORP

Biotech · Private

Autologous therapeutic vaccine made from patient-specific tumor membrane vesicles conjugated to immunostimulatory molecules for triple negative breast cancer treatment

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · metaclipse.com

Sector: Biotech
Total capital: $10.5M

Federal grants: $5.8M; 8 awards · 2017–2022; Rank in peer group#80 of 326
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $4.7M; 3 awards · Health and Human S; Rank in Biotech#84 of 4373
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Sep 2025Federal contractHealth and Human S · SBIR Concept Award For Development Of Therapeutic Or Preventative Technologies For Treatment Or Prevention Of Pediatric Cancers And/or Rare Cancers$300K
Aug 2022Federal grantHealth and Human S · Phase II · Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer$59K
Aug 2022Federal grantHealth and Human S · Phase II · Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer$939K
Apr 2022Federal grantHealth and Human S · Phase II · Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer$35K
Sep 2021Federal grantHealth and Human S · Phase II · Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer$1.1M
Aug 2019Federal contractHealth and Human S · Development Of Membrane Anchored Cytokines As Novel Vaccine Adjuvants For The Elderly.$4.1M
Feb 2019Federal grantHealth and Human S · Phase II · IND enabling studies for a personalized immunotherapy for triple negative breast cancer$80K

Show 4 earlier federal awards

Jul 2018Federal grantHealth and Human S · Phase II · Membrane-based vaccine with checkpoint blockade for triple negative breast cancer$1.1M
Sep 2017Federal grantHealth and Human S · Phase II · Membrane-based vaccine with checkpoint blockade for triple negative breast cancer$701K
Sep 2017Federal grantHealth and Human S · Phase II · IND enabling studies for a personalized immunotherapy for triple negative breast cancer$1.9M
Jul 2017Federal contractHealth and Human S · Igf::ot::igf Development Of Membrane Anchored Cytokines As Novel Vaccine Adjuvants For The Elderly$230K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 326 peers

Line = median

Biotech · Molecule

Federal grants#80 · top 25%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

QRONO, INCSimilar federal contract value in Biotech · $4.9M in contracts
SIGMOVIR BIOSYSTEMS, INC.Similar federal contract value in Biotech · $4.9M in contracts
MIMEDX GROUP, INC.Similar federal contract value in Biotech · $4.8M in contracts
Biomedical Research Models, Inc.Similar federal contract value in Biotech · $4.6M in contracts
SORRENTO THERAPEUTICS, INC.Similar federal contract value in Biotech · $4.6M in contracts
FD NEUROTECHNOLOGIES CONSULTING & SERVICES, INC.Similar federal contract value in Biotech · $4.6M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.